Combined Aspirin and Cilostazol Treatment is Associated with Reduced Platelet Aggregation and Prevention of Exercise-Induced Platelet Activation

European Journal of Vascular and Endovascular Surgery

Volumn 37, Issue 5, 2009, Pages 604-610

  Cleanthis, M ^a,b   Bhattacharya, V ^a   Smout, J ^b   Ashour, H ^a   Stansby, G ^b  

^a QUEEN ELIZABETH II HOSPITAL   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Aspirin; Cilostazol; Exercise; Platelet aggregation

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; GLYCOPROTEIN IB ALPHA; PADGEM PROTEIN; PLACEBO;

ADULT; AGED; ARTERY DISEASE; ARTICLE; CLAUDICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TREADMILL EXERCISE;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ASPIRIN; BLOOD COAGULATION; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EXERCISE TEST; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; INTERMITTENT CLAUDICATION; MALE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; TETRAZOLES; TREATMENT OUTCOME;

EID: 64749084830     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2009.01.008     Document Type: Article

References (27)

1. Thompson P.D., Zimet R., Forbes W.P., and Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 90 12 (2002 Dec 15) 1314-1319
2. Robless P., Mikhailidis D.P., and Stansby G.P. Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev 1 (2008) CD003748
3. Tjon J.A., and Riemann L.E. Treatment of intermittent claudication with pentoxifylline and cilostazol. Am J Health Syst Pharm 58 6 (2001 Mar 15) 485-493 [quiz 494-6]
4. Kariyazono H., Nakamura K., Shinkawa T., Yamaguchi T., Sakata R., and Yamada K. Inhibition of platelet aggregation and the release of P-selectin from platelets by cilostazol. Thromb Res 101 6 (2001 Mar 15) 445-453
5. Biondi-Zoccai G.G., Lotrionte M., Anselmino M., Moretti C., Agostoni P., Testa L., et al. Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. Am Heart J 155 6 (2008 Jun) 1081-1089
6. Douglas J.S., Holmes D.R., Kereiakes D.J., Grines C.L., Block E., Ghazzal Z.M., et al. Coronary stent restenosis in patients treated with cilostazol. Circulation 112 18 (2005 Nov 1) 2826-2832
7. Shinohara Y., Gotoh F., Tohgi H., Hirai S., Terashi A., Fukuuchi Y., et al. Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study. Cerebrovasc Dis 26 1 (2008) 63-70
8. Huang Y., Cheng Y., Wu J., Li Y., Xu E., Hong Z., et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol 7 6 (2008 Jun) 494-499
9. Matsumoto M. Cilostazol in secondary prevention of stroke: impact of the cilostazol stroke prevention study. Atheroscler Suppl 6 4 (2005 Dec 15) 33-40
10. Wilhite D.B., Comerota A.J., Schmieder F.A., Throm R.C., Gaughan J.P., and Rao A.K. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg 38 4 (2003 Oct) 710-713
11. Robless P.A., Tegos T.J., Okonko D., Mansfield A.O., Nicolaides A.N., Mikhailidis D.P., et al. Platelet activation during carotid endarterectomy and the antiplatelet effect of dextran 40. Platelets 13 4 (2002 Jun) 231-239
12. Smout J.D., Mikhailidis D.P., Shenton B.K., and Stansby G. Combination antiplatelet therapy in patients with peripheral vascular bypass grafts. Clin Appl Thromb Hemost 10 1 (2004 Jan) 9-18
13. Cleanthis M., Smout J., Bhattacharya V., Ashour H., Shenton B., and Stansby G. Treadmill exercise in claudicants on aspirin results in improved antioxidant status but only minimal platelet activation. Platelets 16 8 (2005 Dec) 446-452
14. Robless P.A., Okonko D., Lintott P., Mansfield A.O., Mikhailidis D.P., and Stansby G.P. Increased platelet aggregation and activation in peripheral arterial disease. Eur J Vasc Endovasc Surg 25 1 (2003 Jan) 16-22
15. Onoda K., Ohashi K., Hashimoto A., Okuda M., Shimono T., Nishikawa M., et al. Inhibition of platelet aggregation by combined therapy with aspirin and cilostazol after off-pump coronary artery bypass surgery. Ann Thorac Cardiovasc Surg 14 4 (2008 Aug) 230-237
16. Tanigawa T., Nishikawa M., Kitai T., Ueda Y., Okinaka T., Makino K., et al. Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention. Am J Cardiol 85 9 (2000 May 1) 1054-1059
17. Inoue T., Uchida T., Sakuma M., Imoto Y., Ozeki Y., Ozaki Y., et al. Cilostazol inhibits leukocyte integrin mac-1, leading to a potential reduction in restenosis after coronary stent implantation. J Am Coll Cardiol 44 7 (2004 Oct 6) 1408-1414
18. Nomura S., Inami N., Iwasaka T., and Liu Y. Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: therapeutic effects by cilostazol and potentiation by dipyridamole. Platelets 15 3 (2004 May) 167-172
19. Inoue T., Sohma R., and Morooka S. Cilostazol inhibits the expression of activation-dependent membrane surface glycoprotein on the surface of platelets stimulated in vitro. Thromb Res 93 3 (1999 Feb 1) 137-143
20. Bärtsch P. Platelet activation with exercise and risk of cardiac events. Lancet 354 9192 (1999 Nov 20) 1747-1748
21. Yamazaki M., Uchiyama S., Xiong Y., Nakano T., Nakamura T., and Iwata M. Effect of remnant-like particle on shear-induced platelet activation and its inhibition by antiplatelet agents. Thromb Res 115 3 (2005) 211-218
22. Ito H., Miyakoda G., and Mori T. Cilostazol inhibits platelet-leukocyte interaction by suppression of platelet activation. Platelets 15 5 (2004 Aug) 293-301
23. Tamai Y., Takami H., Nakahata R., Ono F., and Munakata A. Comparison of the effects of acetylsalicylic acid, ticlopidine and cilostazol on primary hemostasis using a quantitative bleeding time test apparatus. Haemostasis 29 5 (1999) 269-276
24. Kawata M., Kuramoto E., Kataoka T., Saito A., Adachi K., Matsuura A., et al. Comparative inhibitory effects of cilostazol and ticlopidine on subacute stent thrombosis and platelet function in acute myocardial infarction patients with percutaneous coronary intervention. Int Heart J 46 1 (2005 Jan) 13-22
25. Kariyazono H., Nakamura K., Arima J., Ayukawa O., Onimaru S., Masuda H., et al. Evaluation of anti-platelet aggregatory effects of aspirin, cilostazol and ramatroban on platelet-rich plasma and whole blood. Blood Coagul Fibrinolysis 15 2 (2004 Mar) 157-167
26. Mallikaarjun S., Forbes W.P., and Bramer S.L. Interaction potential and tolerability of the coadministration of cilostazol and aspirin. Clin Pharmacokinet 37 Suppl. 2 (1999) 87-93
27. Takahashi S., Oida K., Fujiwara R., Maeda H., Hayashi S., Takai H., et al. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol 20 6 (1992 Dec) 900-906